Lilly raised sales guidance for third time this year as Zepbound sales soar. Its stock is rallying.
The drugmaker continues to dominate the market for prescription weight-loss drugs in the U.S.
AI brief
Pulse reads the full article- What happened
- Why it matters
- What to watch
Sign in to get the AI brief. Pulse explains what happened, why it matters, what to watch and who's exposed. Free for members.
Sign in to read the brief
